Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Change in Accured Expenses: 2015-2025

Historic Change in Accured Expenses for Cartesian Therapeutics (RNAC) over the last 10 years, with Sep 2025 value amounting to -$432,000.

  • Cartesian Therapeutics' Change in Accured Expenses fell 172.97% to -$432,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.5 million, marking a year-over-year increase of 61.40%. This contributed to the annual value of -$6.7 million for FY2024, which is 144.15% down from last year.
  • Latest data reveals that Cartesian Therapeutics reported Change in Accured Expenses of -$432,000 as of Q3 2025, which was up 78.79% from -$2.0 million recorded in Q2 2025.
  • Over the past 5 years, Cartesian Therapeutics' Change in Accured Expenses peaked at $3.2 million during Q2 2022, and registered a low of -$6.4 million during Q1 2024.
  • Moreover, its 3-year median value for Change in Accured Expenses was -$1.1 million (2023), whereas its average is -$1.3 million.
  • Per our database at Business Quant, Cartesian Therapeutics' Change in Accured Expenses skyrocketed by 716.67% in 2023 and then slumped by 222.78% in 2024.
  • Over the past 5 years, Cartesian Therapeutics' Change in Accured Expenses (Quarterly) stood at -$679,000 in 2021, then surged by 332.25% to $1.6 million in 2022, then plummeted by 171.21% to -$1.1 million in 2023, then soared by 203.56% to $1.2 million in 2024, then crashed by 172.97% to -$432,000 in 2025.
  • Its last three reported values are -$432,000 in Q3 2025, -$2.0 million for Q2 2025, and -$2.2 million during Q1 2025.